Clinical trialPhase 1Not yet recruiting
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 May 2026
- Expected end
- May 2030
- Enrollment
- 96 participants
- Sites
- 1
- Primary outcomes
- STEP A and STEP B: DLT; Safety (AE); Safety (SAEs); Safety (DILI)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 5 May 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.